ライフサイエンスコーパス: DOTATATE

1 [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-DOTATATE).

2 n only one of the scans were found by (64)Cu-DOTATATE.

3 ant clinical role in combination with (68)Ga-DOTATATE.

4 was compared with the SSTR2 agonist (177)Lu-DOTATATE.

5 icantly more lesions were detected by (64)Cu-DOTATATE.

6 n nontumor tissue was higher than for (68)Ga-DOTATATE.

7 for both [(64)Cu]Cu-DOTATATE and [(68)Ga]Ga-DOTATATE.

8 of the current clinical gold standard (68)Ga-DOTATATE.

9 uroendocrine tumors, who were evaluated with DOTATATE.

10 24, 96, and 168 h after infusion of (177)Lu-DOTATATE.

11 crine tumors treated with PRRT using (177)Lu-DOTATATE.

12 though lower than those observed with (68)Ga-DOTATATE.

13 and 3 h after injection of 200 MBq of (64)Cu-DOTATATE.

14 calculated as 9.6E-02 mSv/MBq for [(55)Co]Co-DOTATATE.

15 after injection of (68)Ga-DOTATOC or (68)Ga-DOTATATE.

16 guideline for the administration of (177)Lu-DOTATATE.

17 iopharmaceuticals, (90)Y-DOTATOC and (177)Lu-DOTATATE.

18 le tumor status changed the uptake of (68)Ga-DOTATATE.

19 dy images for both (68)Ga-DOTATOC and (68)Ga DOTATATE.

20 roendocrine tumors to receive either (177)Lu-Dotatate (116 patients) at a dose of 7.4 GBq every 8 wee

21 polycythemia prospectively underwent (68)Ga-DOTATATE (13 patients), (18)F-FDG (13 patients), (18)F-f

22 ng TRT strategies include the use of (177)Lu-DOTATATE, (131)I-metaiodobenzylguanidine, Bexxar, and Ze

23 e-dose GMX1778, 28 d for single-dose (177)Lu-DOTATATE, 35 d for 3 weekly doses of GMX1778, and 98 d f

24 we compared the 3 radioconjugates [(68)Ga]Ga-DOTATATE, [(64)Cu]Cu-DOTATATE, and [(55)Co]Co-DOTATATE b

25 dy tested the efficacy of gallium-68-labeled DOTATATE ((68)Ga-DOTATATE), a somatostatin receptor subt

26 yclododecane tetraacetic acid octreotate (or DOTATATE), (68)Ga prostate-specific membrane antigen, an

27 statin analogs (e.g., (68)Ga-DOTATOC, (68)Ga-DOTATATE, (68)Ga-DOTANOC, and (64)Cu-DOTATATE) now offer

28 treated with semiefficient doses of (177)Lu-DOTATATE (7.5 MBq, intravenously) or the nicotineamide p

29 atients had PHD after treatment with (177)Lu-DOTATATE: 8 patients (2.9%) developed a hematopoietic ne

30 iagnostic sensitivity and accuracy of (64)Cu-DOTATATE (97% for both) were significantly better than t

31 icacy of gallium-68-labeled DOTATATE ((68)Ga-DOTATATE), a somatostatin receptor subtype-2 (SST2)-bind

32 and Drug Administration approval of (177)Lu-DOTATATE, a form of PRRT, in 2018 for use in gastroenter

33 Conclusion:(68)Ga-DOTATATE activity on PET in recently symptomatic carotid

34 ts, and explored the mechanism of any plaque DOTATATE activity with immunohistochemistry in resected

35 on of 202 MBq (range, 183-232 MBq) of (64)Cu-DOTATATE after a diagnostic contrast-enhanced CT scan.

36 external-beam radiotherapy (EBRT) or (177)Lu-DOTATATE, after which the number of gammaH2AX foci and t

37 head-to-head basis the performance of (64)Cu-DOTATATE and (111)In-diethylenetriaminepentaacetic acid

38 The (68)Ga-DOTATATE and (18)F-FDG PET/CT findings were discordant i

39 The relation between complementary (68)Ga-DOTATATE and (18)F-FDG PET/CT results of 27 GEPNET patie

40 ndocrine tumors (NETs) underwent both (68)Ga-DOTATATE and (18)F-FDG PET/CT.

41 imed to assess the clinical impact of (68)Ga-DOTATATE and (18)F-FDG with respect to the management pl

42 additional true lesions were found by (64)Cu-DOTATATE and (68)Ga-DOTATOC in 13 and 3 patients, respec

43 nt-based sensitivity was the same for (64)Cu-DOTATATE and (68)Ga-DOTATOC in this cohort, significantl

44 e NET patients were scanned with both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT and compared on a hea

45 e NET patients were scanned with both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT and compared on a hea

46 ns were concordantly detected on both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT scans, whereas an add

47 ns were concordantly detected on both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT scans, whereas an add

48 , such as 0.021 +/- 0.003 mSv/MBq for (68)Ga-DOTATATE and (68)Ga-DOTATOC, mainly because of higher up

49 r-to-kidney dose ratio compared with (177)Lu-DOTATATE and (90)Y-OPS201.

50 After (177)Lu-DOTATATE and 3 weekly doses of GMX1778, none of the tumo

51 than the corresponding ratios for [(64)Cu]Cu-DOTATATE and 5 (P < 0.001) times higher than that of [(6

52 rior image contrast compared with [(64)Cu]Cu-DOTATATE and [(68)Ga]Ga-DOTATATE for PET imaging of soma

53 were comparable to those for both [(64)Cu]Cu-DOTATATE and [(68)Ga]Ga-DOTATATE.

54 s, with some exceptions, such as for (177)Lu-DOTATATE and for kidney dosimetry in different radiophar

55 ework was promising for dosimetry of (177)Lu-DOTATATE and for kidney dosimetry of different radiophar

56 and 98 d for combined treatment with (177)Lu-DOTATATE and GMX1778 x 1.

57 h neuroendocrine tumors treated with (177)Lu-DOTATATE and imaged up to 4 times between days 0 and 7 u

58 l patients underwent both PET/CT with (64)Cu-DOTATATE and SPECT/CT with (111)In-DTPA-OC within 60 d.

59 r to literature values for (18)F-FDG, (68)Ga-DOTATATE, and (68)Ga-PSMA-11, an examination with 200 MB

60 ioconjugates [(68)Ga]Ga-DOTATATE, [(64)Cu]Cu-DOTATATE, and [(55)Co]Co-DOTATATE by PET/CT imaging in N

61 str agonists, such as (68)Ga-DOTATOC, (68)Ga-DOTATATE, and [(68)Ga-DOTA,1-Nal(3)]octreotide ((68)Ga-D

62 (18)F-FDA are superior to (18)F-FDG, (68)Ga-DOTATATE, and CT/MRI and should be the radiopharmaceutic

63 No adverse events were related to (64)Cu-DOTATATE, and no serious adverse events were observed.

64 isease were imaged with (18)F-FDG and (68)Ga-DOTATATE, and research subjects were imaged with experim

65 (68)Ga-DOTATATE approval by the U.S. Food and Drug Administrati

66 (68)Ga-DOTATOC and (68)Ga-DOTATATE are radiolabeled somatostatin analogs used for

67 sitate to recommend implementation of (64)Cu-DOTATATE as a replacement for (111)In-DTPA-OC.

68 -DTPA-OC) as a basis for implementing (64)Cu-DOTATATE as a routine.

69 0.001) times higher than that of [(68)Ga]Ga-DOTATATE at 1 h.

70 0.001) times higher than that of [(64)Cu]Cu-DOTATATE at 24 h.

71 mors treated with repeated cycles of (177)Lu-DOTATATE at 8-wk intervals.

72 records of all patients treated with (177)Lu-DOTATATE at Moffitt Cancer Center between April 2018 and

73 treated with at least 2 fractions of (177)Lu-DOTATATE at Sahlgrenska University Hospital.

74 ATATE PET/CT image analysis and total (68)Ga-DOTATATE-Avid tumor volume ((68)Ga-DOTATATE TV) was dete

75 a post hoc head-to-head comparison of (68)Ga-DOTATATE-based and (111)In-pentetreotide-based Krenning

76 We confirmed (68)Ga-DOTATATE binding in macrophages and excised carotid plaq

77 Uptake of (64)Cu-DOTATATE, but not of (68)Ga-DOTATOC, was correlated with

78 (55)Co and (64)Cu were labeled with DOTATATE by heating in a sodium acetate buffer and 4-(2-

79 OTATATE, [(64)Cu]Cu-DOTATATE, and [(55)Co]Co-DOTATATE by PET/CT imaging in NOD-SCID mice bearing subc

80 ing in vitro cell lines treated with (177)Lu-DOTATATE, clonogenic survival decreased and gammaH2AX fo

81 Conclusion: [(55)Co]Co-DOTATATE demonstrated superior image contrast compared w

82 Using the (64)Cu-DOTATATE dose identified in the dose-ranging study, 3 in

83 ched for patients receiving RLT with (177)Lu-DOTATATE, -DOTATOC, or -prostate-specific membrane antig

84 T/CT 4 d after the administration of (177)Lu-DOTATATE/DOTATOC provides a 3-dimensional dose map and c

85 risks and benefit of treatment with (177)Lu-DOTATATE/DOTATOC.

86 (68)Ga-DOTATATE estimated sensitivity, 90.9% (95% confidence in

87 scanning window of at least 3 h make (64)Cu-DOTATATE favorable and easy to use in the clinical setti

88 Referring physicians categorized the DOTATATE findings on the basis of the written PET report

89 diotracers; and in 50 (48.1%), on the (68)Ga-DOTATATE findings.

90 th the current clinical gold standard (68)Ga-DOTATATE for high-quality imaging of somatostatin recept

91 ficacy and safety supports the use of (68)Ga-DOTATATE for imaging of NETs where it is available.

92 ared with [(64)Cu]Cu-DOTATATE and [(68)Ga]Ga-DOTATATE for PET imaging of somatostatin receptor-expres

93 DOTA-derived somatostatin analogs DOTATOC or DOTATATE for PET.

94 We performed a systematic review of (68)Ga-DOTATATE for safety and efficacy compared with octreotid

95 Recently, we introduced (64)Cu-DOTATATE for SRI, and we hypothesized that uptake of thi

96 With the recent approval of (177)Lu-DOTATATE for use in gastroenteropancreatic neuroendocrin

97 ecanetetraacetic acid tyrosine-3-octreotate (DOTATATE) for the treatment of neuroendocrine tumours an

98 interval [CI], 50.0 to 76.8) in the (177)Lu-Dotatate group and 10.8% (95% CI, 3.5 to 23.0) in the co

99 survival, 14 deaths occurred in the (177)Lu-Dotatate group and 26 in the control group (P=0.004).

100 9%, respectively, of patients in the (177)Lu-Dotatate group as compared with no patients in the contr

101 The response rate was 18% in the (177)Lu-Dotatate group versus 3% in the control group (P<0.001).

102 intramuscularly at a dose of 30 mg) ((177)Lu-Dotatate group) or octreotide LAR alone (113 patients) a

103 in less than 10% of patients in the (177)Lu-Dotatate group.

104 Conclusion:(64)Cu-DOTATATE has advantages over (68)Ga-DOTATOC in the detec

105 the radiolabeled somatostatin analog (177)Lu-DOTATATE has had a significant impact on management of n

106 PET using the SSTR2 analog (68)Ga-DOTATATE has recently been introduced for imaging of men

107 ment for neuroendocrine tumors, with (177)Lu-DOTATATE having acquired marketing authorization in Euro

108 In 84 patients (75%), (64)Cu-DOTATATE identified more lesions than (111)In-DTPA-OC an

109 o direct comparison of octreotide and (68)Ga-DOTATATE imaging for diagnosis and staging in an unbiase

110 (68)Ga-DOTATATE imaging is a promising approach for detecting G

111 compared with (111)In-pentetreotide, (68)Ga-DOTATATE imaging should be used instead of (111)In-pente

112 CT images at 24 h after injection of (177)Lu-DOTATATE in 4 hybrid methods: L4-SPECT used the activity

113 ously shown the clinical potential of (64)Cu-DOTATATE in a small first-in-human feasibility study.

114 tigation of the in vivo stability of (177)Lu-DOTATATE in humans affected by neuroendocrine tumors.

115 of the PET tracers (68)Ga-DOTATOC and (64)Cu-DOTATATE in large arteries, in the assessment of atheros

116 cases (36%) lesions were detected by (64)Cu-DOTATATE in organs not identified as disease-involved by

117 fficacy and safety of lutetium-177 ((177)Lu)-Dotatate in patients with advanced, progressive, somatos

118 e relationship during treatment with (177)Lu-DOTATATE in patients with and without skeletal metastase

119 ic dysfunction (PHD) after PRRT with (177)Lu-DOTATATE in patients with gastroenteropancreatic neuroen

120 ) SSA treatment changes the uptake of (68)Ga-DOTATATE in patients with NETs.

121 n, there was a measureable amount of (177)Lu-DOTATATE in patients, which is mainly governed by retent

122 bserved, with the fraction of intact (177)Lu-DOTATATE in plasma decreasing rapidly to 23% +/- 5% (mea

123 tors, suggesting a potential role for (64)Cu-DOTATATE in the assessment of atherosclerosis.

124 uptake values in PET/CT imaging than (68)Ga-DOTATATE in vivo.

125 Diagnostic performance calculated for (64)Cu-DOTATATE included sensitivity, specificity, negative pre

126 Adverse events were recorded from (64)Cu-DOTATATE injection through 48 h after injection.

127 edical complications before and after (68)Ga-DOTATATE injection.

128 Importantly, and in contrast to (177)Lu-DOTATATE, injection of 10, 200, and 2,000 pmol of (177)L

129 he tumor may react differentially to (177)Lu-DOTATATE irradiation.

130 Molecular radiotherapy using (177)Lu-DOTATATE is a most effective treatment for somatostatin

131 (64)Cu-DOTATATE is a new PET tracer that has been shown to be f

132 receptor radionuclide therapy using (177)Lu-DOTATATE is based on patient imaging during the first we

133 th these results, we demonstrate that (64)Cu-DOTATATE is far superior to (111)In-DTPA-OC in diagnosti

134 Conclusion: The in vivo stability of (177)Lu-DOTATATE is much lower than previously assumed, with the

135 eceptor imaging with (68)Ga-DOTATATE PET/CT (DOTATATE) is increasingly used for managing patients wit

136 Referring physicians reported that DOTATATE led to a change in suspicion for metastatic dis

137 nflammatory" M1 macrophages, specific (68)Ga-DOTATATE ligand binding to SST2 receptors occurred in CD

138 (68)Ga-DOTATATE mean of maximum tissue-to-blood ratios (mTBRmax

139 (68)Ga-DOTATATE mTBRmax predicted high-risk coronary computed t

140 (n = 8) after the administration of (177)Lu-DOTATATE (n = 22) or (177)Lu-DOTATOC (n = 7).

141 (68)Ga-DOTATATE, (68)Ga-DOTANOC, and (64)Cu-DOTATATE) now offers improved sensitivity.

142 gamma-camera and serum measurements ((111)In-DOTATATE) of patients with meningioma or neuroendocrine

143 OTATOC showed 26 lesions not found on (64)Cu-DOTATATE, of which 7 were found to be true-positive on f

144 rotic inflammation and confirmed that (68)Ga-DOTATATE offers superior coronary imaging, excellent mac

145 after injection of (68)Ga-DOTATOC and (68)Ga-DOTATATE on consecutive days.

146 after injection of (68)Ga-DOTATOC and (68)Ga-DOTATATE on consecutive days.

147 sicians demonstrates a substantial impact of DOTATATE on the intended management of patients with neu

148 ng physicians' perspectives on the impact of DOTATATE on the management of neuroendocrine tumors.

149 ses newer SSTR-based PET imaging with (68)Ga-DOTATATE or (68)Ga-DOTATOC as a prerequisite for the adm

150 7)Lu- or (90)Y-labeled somatostatin analogs (DOTATATE or DOTATOC).

151 e tumor xenografts were treated with (177)Lu-DOTATATE or sham-treated and coinjected with (111)In-ant

152 is for both (18)F-FDG (P = 0.037) and (68)Ga-DOTATATE (P = 0.047).

153 tetium 177 ((177)Lu) DOTA-0-Tyr3-Octreotate (DOTATATE) peptide receptor radionuclide therapy (PRRT) i

154 stic pair is the (68)Ga- and (177)Lu-labeled DOTATATE peptides, which are used to image neuroendocrin

155 We validated (68)Ga-DOTATATE PET as a novel marker of atherosclerotic inflam

156 n only the 1-h images or only the 3-h (64)Cu-DOTATATE PET images) were considered true if found on si

157 (68)Ga-DOTATATE PET imaging was compared to [(18)F]FDG PET imag

158 gs substantiate an important role for (68)Ga-DOTATATE PET in meningioma management.

159 Preoperative MR imaging and (68)Ga-DOTATATE PET scans were fused and used for a spatially p

160 Coronary (68)Ga-DOTATATE PET scans were readable in all patients.

161 NA was highly correlated with in vivo (68)Ga-DOTATATE PET signals (r = 0.89; 95% confidence interval

162 mph node) detected on 3-h but not 1-h (64)Cu-DOTATATE PET that did not alter the patient's disease st

163 lesions (visible on both 1-h and 3-h (64)Cu-DOTATATE PET) and 5 discordant lesions, of which 4 were

164 er of lesions detected on 1-h and 3-h (64)Cu-DOTATATE PET.

165 Somatostatin receptor imaging with (68)Ga-DOTATATE PET/CT (DOTATATE) is increasingly used for mana

166 (68)Ga-DOTATATE PET/CT and (111)In-pentetreotide scans were obt

167 (68)Ga-DOTATATE PET/CT and (111)In-pentetreotide scans were sig

168 nalyzed the diagnostic performance of (68)Ga-DOTATATE PET/CT and contrast-enhanced MRI (CE-MRI) for t

169 the performance and interpretation of (68)Ga-DOTATATE PET/CT and describes its role in the diagnostic

170 st study to report the association of (64)Cu-DOTATATE PET/CT and outcome in patients with NENs, tumor

171 patient populations: those undergoing (68)Ga-DOTATATE PET/CT before starting LA SSA treatment and at

172 of somatostatin receptor imaging with (68)Ga-DOTATATE PET/CT by interfering with tracer-receptor bind

173 (68)Ga-DOTATATE PET/CT changed treatment in 36% of participants

174 (68)Ga-DOTATATE PET/CT combined with CT or liver MRI changed ca

175 o evaluate the safety and efficacy of (68)Ga-DOTATATE PET/CT compared with (111)In-pentetreotide imag

176 (68)Ga-DOTATATE PET/CT correctly identified 3 patients for pept

177 irst 8 y of patient data from a large (68)Ga-DOTATATE PET/CT database in order to establish the impac

178 oms but negative biochemical testing, (68)Ga-DOTATATE PET/CT detected lesions in 65.2% of patients, 4

179 (68)Ga-DOTATATE PET/CT enables detection of meningioma tissue b

180 Conclusion:(68)Ga-DOTATATE PET/CT enables improved detection of the transo

181 ts were selected from 327 consecutive (68)Ga-DOTATATE PET/CT examinations for evaluation of confirmed

182 onclusion: The imaging time window of (64)Cu-DOTATATE PET/CT for patients with NENs can be expanded f

183 ve implications for interpretation of (68)Ga-DOTATATE PET/CT for response assessment after SSA therap

184 In four of 14 patients (28.6%), (68)Ga-DOTATATE PET/CT found a previously unknown primary tumor

185 (68)Ga-DOTATATE PET/CT identified more lesions than other imagi

186 All patients underwent (68)Ga-DOTATATE PET/CT image analysis and total (68)Ga-DOTATATE

187 The interpretation of (68)Ga-DOTATATE PET/CT images for NET staging is consistent amo

188 red, on a head-to-head basis, sets of (64)Cu-DOTATATE PET/CT images from 35 patients with NENs scanne

189 (64)Cu-DOTATATE PET/CT imaging 1 h after injection is excellent

190 (68)Ga-DOTATATE PET/CT imaging detected 95.1% of lesions (95% C

191 Current reports suggest that (68)Ga-DOTATATE PET/CT imaging improves diagnosis and staging o

192 (68)Ga-DOTATATE PET/CT imaging provides important information f

193 (68)Ga-DOTATATE PET/CT in comparison to CE-MRI performed at a h

194 We evaluated observer agreement for (68)Ga-DOTATATE PET/CT interpretations in patients with neuroen

195 Conclusion: (64)Cu-DOTATATE PET/CT is a safe imaging technique that provide

196 )Cu-SARTATE PET/CT obtained at 4 h to (68)Ga-DOTATATE PET/CT obtained at 1 h indicated comparable or

197 (68)Ga-DOTATATE PET/CT of the neck was performed before surgery

198 gated the definite clinical impact of (68)Ga-DOTATATE PET/CT on managing patients with neuroendocrine

199 udy confirmed a significant impact of (68)Ga-DOTATATE PET/CT on the intended management of patients w

200 (68)Ga-DOTATATE PET/CT provides information on the location of

201 ospectively studied 130 patients with (68)Ga-DOTATATE PET/CT referred for initial or subsequent manag

202 (68)Ga-DOTATATE PET/CT resulted in intended management changes

203 ned by changes in treatment plan when (68)Ga-DOTATATE PET/CT results were added to all prior imaging,

204 during the interval between baseline (68)Ga-DOTATATE PET/CT scan and follow-up imaging (14.0 +/- 6.1

205 Interobserver reproducibility of (68)Ga-DOTATATE PET/CT scan interpretation was measured between

206 uroendocrine tumors and who underwent (68)Ga-DOTATATE PET/CT scanning before and after receiving long

207 (68)Ga-DOTATATE PET/CT scanning is a widely accepted method for

208 (68)Ga-DOTATATE PET/CT scanning is safe and influences manageme

209 Of the 1,258 (68)Ga-DOTATATE PET/CT scans completed, 75.7% were positive and

210 tween May 2005 and August 2013, 1,258 (68)Ga-DOTATATE PET/CT scans were obtained in 728 patients with

211 ors underwent both (68)Ga-DOTATOC and (64)Cu-DOTATATE PET/CT scans, in random order.

212 irect impact on the interpretation of (68)Ga-DOTATATE PET/CT scans.

213 ated patients with NENs who underwent (64)Cu-DOTATATE PET/CT SRI in 2 prospective studies.

214 y of prediction of PFS at 24 mo after (64)Cu-DOTATATE PET/CT SRI was moderate, limiting the value on

215 (68)Ga-DOTATATE PET/CT was equivalent or superior to (111)In-pe

216 (68)Ga-DOTATATE PET/CT was performed on 50 patients with known

217 tumor SSTR density as visualized with (64)Cu-DOTATATE PET/CT was prognostic for PFS but not OS.

218 (68)Ga-DOTATATE PET/CT was prospectively performed in 20 patien

219 vival, and change in management after (68)Ga-DOTATATE PET/CT were evaluated.

220 The most common indications for (68)Ga-DOTATATE PET/CT were follow-up (24.4%) and initial tumor

221 neuroendocrine tumors, we expect that (68)Ga-DOTATATE PET/CT will become the preferred functional ima

222 tomography with computed tomography ((68)Ga-DOTATATE PET/CT) is a sensitive imaging technique for de

223 Patients were imaged using (68)Ga-DOTATATE PET/CT, (111)In-pentetreotide planar scintigrap

224 spective study of patients undergoing (68)Ga-DOTATATE PET/CT, (111)In-pentetreotide single-photon emi

225 On the basis of findings with (68)Ga-DOTATATE PET/CT, 43 of 131 patients (32.8%) had a change

226 All patients were evaluated with gallium 68 DOTATATE PET/CT, and in cases of high-grade tumors, they

227 vestigated the prognostic accuracy of (68)Ga-DOTATATE PET/CT-based analysis of tumor volume in patien

228 r predicting PFS (57%) at 24 mo after (64)Cu-DOTATATE PET/CT.

229 lesions (P = 0.016) were detected on (68)Ga-DOTATATE PET/CT.

230 heochromocytomas/paragangliomas using (68)Ga-DOTATATE PET/CT.

231 prediction of outcome at 24 mo after (64)Cu-DOTATATE PET/CT.

232 /=500 scans or >/=5 y experience with (68)Ga-DOTATATE PET/CT; n = 3).

233 e (<500 scans or <5 y experience with (68)Ga-DOTATATE PET/CT; n = 4) or a high level of experience (>

234 for uptake on (68)Ga-DOTA-octreotate ((68)Ga-DOTATATE) PET/CT underwent serial PET/CT imaging at 30 m

235 ely determine the clinical utility of (68)Ga-DOTATATE positron emission tomography (PET)/computed tom

236 (68)Gallium-DOTATATE positron emission tomography with computed tomo

237 Four cycles of (177)Lu-DOTATATE PRRT resulted in a morphological response and a

238 kflow that has been successful since (177)Lu DOTATATE PRRT was approved by the U.S. Food and Drug Adm

239 demonstrate that the investigational (64)Cu-DOTATATE radiopharmaceutical may provide diagnostic and

240 sed significantly over time, with [(55)Co]Co-DOTATATE reaching the highest ratio of all radioconjugat

241 0.98 and 0.93 for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

242 (slope, 0.74) for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

243 )Lu-OPS201 than for (90)Y-OPS201 and (177)Lu-DOTATATE, respectively.

244 le-body images for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

245 (slope, 0.88) for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

246 (slope, 0.88) for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

247 Treatment with (177)Lu-Dotatate resulted in markedly longer progression-free su

248 01 (10 pmol) and 6.4 h (5.4-7.3) for (177)Lu-DOTATATE, resulting in a 2.5-times-higher tumor dose for

249 (64)Cu-DOTATATE showed 42 lesions not found on (68)Ga-DOTATOC,

250 The mean time interval between the 2 (68)Ga-DOTATATE studies was 9.6 +/- 7.2 mo, and the mean time g

251 dostatin LAR injection and the second (68)Ga-DOTATATE study was 25.1 +/- 14.8 d.

252 to determine the predictive value of (64)Cu-DOTATATE SUV(max) for OS and PFS.

253 The optimal cutoff for (64)Cu-DOTATATE SUV(max) was 43.3 for prediction of PFS, with a

254 est showed significant differences in (68)Ga-DOTATATE SUVmax between tumors with a Ki-67 of less than

255 (68)Ga DOTATATE SUVmax relates to grade and Ki-67 and can be us

256 For (68)Ga-DOTATATE, SUVmax was higher for G1 tumors and lower for

257 ce as many lesions were detected with (64)Cu-DOTATATE than with (111)In-DTPA-OC.

258 ectively determine the lowest dose of (64)Cu-DOTATATE that facilitates diagnostic-quality scans and e

259 10%) to determine the lowest dose of (64)Cu-DOTATATE that produced diagnostic-quality PET/CT images.

260 ptor radionuclide therapy with (90)Y-labeled DOTATATE, the kidney absorbed dose limits the maximum am

261 For [(55)Co]Co-DOTATATE, the tumor-to-liver ratio increased to 65 +/- 1

262 llows monitoring of DNA damage after (177)Lu-DOTATATE therapy and reveals heterogeneous damage respon

263 r perfusion and receptor density for (177)Lu-DOTATATE therapy using physiologically based pharmacokin

264 extent of DNA damage response after (177)Lu-DOTATATE therapy using SPECT imaging with (111)In-anti-g

265 euticals in the same patient, finding (68)Ga-DOTATATE to be more sensitive than octreotide.

266 GMX1778 enhances the efficacy of (177)Lu-DOTATATE treatment and induces a prolonged antitumor res

267 neamide phosphoribosyltransferase on (177)Lu-DOTATATE treatment in a NET model.

268 d bowel obstruction within 3 mo of a (177)Lu-DOTATATE treatment was divided by the total number of pa

269 tive assessment of (68)Ga-DOTATOC and (68)Ga-DOTATATE tumor uptake and as a therapy monitoring tool f

270 tive assessment of (68)Ga-DOTATOC and (68)Ga-DOTATATE tumor uptake.

271 erse correlation between quartiles of (68)Ga-DOTATATE TV and PFS (P = .001) and disease-specific surv

272 emonstrated the prognostic utility of (68)Ga-DOTATATE TV in a large cohort of patients with NETs, in

273 A (68)Ga-DOTATATE TV of 35.8 mL or more was associated with incre

274 A (68)Ga-DOTATATE TV of 7.0 mL or more was associated with higher

275 al (68)Ga-DOTATATE-Avid tumor volume ((68)Ga-DOTATATE TV) was determined.

276 vealed a partial correlation between (177)Lu-DOTATATE uptake and gammaH2AX focus induction between di

277 m of this study was to assess whether (68)Ga-DOTATATE uptake before treatment with long-acting somato

278 (68)Ga-DOTATATE uptake correlates with SSTR2 expression and off

279 rospectively evaluated carotid plaque (68)Ga-DOTATATE uptake in patients with recent carotid events,

280 cting octreotide treatment diminished (68)Ga-DOTATATE uptake in the liver, spleen, and thyroid but di

281 (68)Ga-DOTATATE uptake was measured by drawing regions of inter

282 ver, a systematic correlation between (68)Ga-DOTATATE uptake, SSTR2 expression, and histology (includ

283 ore and the overall maximum uptake of (64)Cu-DOTATATE using SUV (r = 0.4; P = 0.004) as well as targe

284 al case study examples ((18)F-FDG and (68)Ga-DOTATATE) using the motion-correction technique, demonst

285 he prevalence of PHD after PRRT with (177)Lu-DOTATATE was 4% in our patient population.

286 The optimal SPECT scanning time for (177)Lu-DOTATATE was approximately 72 h p.i., whereas 48 h p.i.

287 standardized uptake value (SUVmax) of (68)Ga-DOTATATE was correlated with MR imaging findings, histol

288 on of risk factors and maximum SUV of (64)Cu-DOTATATE was found driven by body mass index, smoking, d

289 vascular uptake of (68)Ga-DOTATOC and (64)Cu-DOTATATE was found, with highest uptake of the latter.

290 most common treatment decision due to (68)Ga-DOTATATE was initiation of peptide receptor radionuclide

291 Report of harm possibly related to (68)Ga-DOTATATE was rare (6 of 974), and no study reported majo

292 Uptake of (64)Cu-DOTATATE was significantly higher than (68)Ga-DOTATOC in

293 In a second clinical study with (68)Ga-DOTATATE, we demonstrated comparable diagnostic image qu

294 ey and tumor-to-muscle ratios for [(55)Co]Co-DOTATATE were 4 (P < 0.001) and 11 (P < 0.001) times hig

295 ns found that effective doses for [(55)Co]Co-DOTATATE were comparable to those for both [(64)Cu]Cu-DO

296 ood samples of 6 patients undergoing (177)Lu-DOTATATE were taken at 0.5, 4, 24, and 96 h after inject

297 studies reporting safety/toxicity for (68)Ga-DOTATATE with 10 subjects or more thought to have NETs.

298 Nine studies compared (68)Ga-DOTATATE with conventional imaging.

299 dies comparing diagnostic accuracy of (68)Ga-DOTATATE with octreotide or conventional imaging for pul

300 d basis the diagnostic performance of (64)Cu-DOTATATE with that of (68)Ga-DOTATOC in NET patients.